TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.

Oncotarget · 2020 · PMC7584235 · PMID 33144917

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a trend towards significanceno p-value reported

There is a trend towards significance in the difference in the growth rates of tumors treated with rhTRAIL IV alone and tumors treated with a combination of 100 mg/kg ONC201 orally and rhTRAIL IV ( p = 0.27, Figure 5A ; p = 0.11, Figure 5B ).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.